Cell surface molecules TSCL1: Culprit behind chronic inflammation and cancers caused by oncogenic viruses

Richard Hunte and Noula Shembade*

Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, The University of Miami, Miami, FL, USA

A vast number of cell surface molecules (CSMs), which are involved in the regulation of inflammation, innate and adaptive immune response, cell death, and the restoration of tissue homeostasis were recently identified. Whereas some of these CSMs serve the role of cell adhesive molecules, others function as costimulatory molecules to lock distinct inflammatory and immune responses [1,2]. In addition, certain CSM heterophilic and homophilic interactions serve the role of either ligands or receptors, or both in this process [3]. CSMs also play a critical role in cell-to-cell communication [4]. The fate of the tissue is determined by the levels of CSMs expressed in a particular tissue. Certain levels of CSM expression are sufficient for their beneficial function; however, altering levels of CSM expression due to infection, injury, or substance abuse play a detrimental role in a particular tissue. Interestingly, the mechanisms of CSM-mediated distinct effects on regulation of inflammation, innate and adaptive immunity, and the optimal levels of CSM expression required for beneficial effects are poorly understood. This review will focus on recent findings on the mechanism of inflammation regulation mediated by a highly upregulated CSM, tumor suppressor in lung cancer-1 (TSCL1), in oncogenic virus infected cells.

Approximately 12-20% of all human cancers worldwide are caused by infections with oncogenic viruses. For example, Human T-cell leukemia virus type 1 (HTLV-1), Kaposi’s sarcoma herpesvirus/human herpesvirus8(KSHV/HHV8), Epstein Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), and human papillomavirus (HPV), are oncogenic viral agents responsible for a large number of human cancers. This review will mainly focus on a CSM-TSCL1 involved in KSHV and HTLV-1 oncogenesis. KSHV is one of the oncogenic viruses responsible for human cancers, including Kaposi’s sarcoma (KS), Primary Effusion Lymphoma (PEL), and the lymphoproliferative disorder Multicentric Castleman’s disease (MCD). Chronic inflammation mediated by KSHV infection plays a decisive role in the development and survival of cancer cells. HTLV-1 is a retrovirus and etiological agent of adult T-cell leukemia (ATL). These viruses encode unique sets of viral genes that regulate viral replication and promote distinct malignancies. KSHV is a DNA virus and encodes several oncogenes, such as KSHV-encoded chemokine receptor or viral G protein-coupled receptor (vGPCR) and antiapoptotic viral Fas-associated death domain-like interleukin-1β-converting enzyme-inhibitory protein (vFLIP). HTLV-1 encodes the Tax trans-activating protein and oncogene. The KSHV-encoded oncogenes vGPCR and vFLIP are key KSHV lytic and latent genes, respectively. Viral oncogenes, vFLIP of KSHV and Tax of HTLV-1 are required for viral transformation, cell proliferation, cell survival and genetic instability. Our published work and preliminary data suggest that TSCL1 is highly induced during KSHV and HTLV-1 de novo infection and is critical for the establishment of KSHV and HTLV-1 latency. In addition, viral oncogenes, vFLIP, vGPCR, and Tax, dysregulate the tumor suppressor function of TSCL1 and hijack it’s function to maintain chronic inflammation required for the KSHV and HTLV-1-induced tumors. TSCL1 expression is critical for the survival of KSHV and HTLV-1-infected tumor cells. However, the mechanisms of viral oncogene-mediated dysregulation of TSCL1 function are poorly understood. TSCL1 is not only expressed on the cell surface but also localized in the cytoplasm and other cell organelles, such as the endoplasmic reticulum and Golgi bodies. Therefore, it will be of great interest for future studies to determine whether the high levels of TSCL1 expressed in KSHV and HTLV-1 infected cells are also involved in virus endocytosis or exocytosis, which could potentially be targeted by small molecules to limit the de novo infection and spread of these oncogenic viruses.

Chronic inflammation mediated by transcription factors including, Nuclear factor-kappaB (NF-kB), Signal transducer and activator of transcription 3 (STAT3), and Nuclear factor of activated T-cells (NFAT), in oncogenic virus-infected cells play critical roles in viral transformation, cell proliferation, cell survival and genetic instability [5]. KSHV and HTLV-1 often establish a life-long asymptomatic latent infection [5]. Infections with KSHV and HTLV-1 can immortalize human primary endothelial cells and B cells, or T cells, respectively [6]. Chronically activated NF-κB pathways mediated by vFLIP and vGPCR of KSHV, or Tax of HTLV-1 are critical for the survival of KSHV and HTLV-1 infected cells [7,8]. We and others have shown that TSCL1 is highly upregulated in KSHV and HTLV-1-infected cells. Interestingly, TSCL1 is a critical molecule for vFLIP, vGPCR and Tax-mediated chronic activation of the IKK kinase complex (IKKα IKKβ, and IKKγ), which is required for the phosphorylation and proteasomal degradation of the NF-κB inhibitor, IκBα. Viral oncogene-mediated degradation of IκBα induces the activation of NF-κB dimers (e.g. p50/p65), which maintains upregulation of several hundred genes, including pro-inflammatory cytokines and chemokines in KSHV and HTLV-1 infected cells (Figure 1) [7,8]. NFAT is chronically activated by HTLV-1 Tax and KSHV vGPCR [7,9]. A recent study suggests that TSCL1 is also critical for vGPCR-mediated chronic activation of NFAT [7]. Although STAT3 is chronically activated in KSHV and HTLV-1-infected tumor cells, it is unknown if TSCL1 is also involved in chronic activation of STAT3 in these virus infected tumor cells. Since TSCL1 is

*Correspondence to: Noula Shembade, Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, The University of Miami, Miami, FL, USA, E-mail: nshembade@med.miami.edu

Key words: TSCL1, HTLV-1, KSHV, NF-kB, NFAT, vFLIP, vGPCR, Tax

Received: April 10, 2019; Accepted: June 24, 2019; Published: June 28, 2019
cri tical for the survival of KSHV and HTLV-1 infected tumor cells, we speculate that TSLC1 may also regulate STAT3 activation in these virus infected cells. Previous studies have shown that several GPCRs activate STAT3 and NF-κB, which contributes to the development of cancers. Although our published results and preliminary data suggest that an interaction of TSLC1 with vGPCR is critical for the activation of NF-κB, it is unknown whether TSLC1 also interacts with host GPCRs, which are involved in the activation of NFAT, STAT3 and NF-κB. Therefore, it will be interesting in future studies to determine whether TSLC1 is also involved in activation of STAT3 and NF-κB in uninfected cells/tissues as part of its normal physiological role.

Conflicting interests

The authors have declared that no competing interests exist.

Acknowledgements

This research was funded by American Cancer Society RSG-16-254-01-MPC. We gratefully acknowledge Dr. Edward Harhaj for review of this manuscript.

References